Prana AGM Investor Conference Call
Prana Biotechnology invites investors unable to attend the Annual General Meeting to participate via teleconference.
Annual Report Filed on Form 20-F with SEC
Prana has announced that it has filed its Annual Report on Form 20-F
Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology
PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture
Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
Scientific Journal Acta Neuropathologica publishes pre-clinical data
Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development
David Stamler, M.D., has joined Prana Biotechnology (ASX PBT, NASDAQ PRAN) as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco.
Prana’s Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer’s & Parkinson’s Diseases
Prana today announced a scientific presentation demonstrating pre-clinical evidence for Prana’s PBT434 as a first-in-class disease modifying therapy for the treatment of Parkinsonian movement disorders that will be featured at the 13th International Conference for Alzheimer’s and Parkinson’s Diseases in Vienna from 29 March 2 April 2017.
Prana Business Update
Prana today provided a business update on its development portfolio of potential neurodegenerative treatments.
Prana AGM investor webcast details
Prana Biotechnology will host a webcast at its Annual General Meeting on Thursday 17th November 2016 at 9.30am AEDT.
Prana provides regulatory update for PBT2 for the treatment of Huntington disease
Prana today announced that is has received further advice from the US Food and Drug Administration (FDA) on the steps necessary to remove the Partial Clinical Hold (PCH) on PBT2, including the requirement to undertake further non-clinical studies.